Are you currently involved in the development of AAV-based gene therapy, specifically with non-human primates (NHP) or other large animals? Whether your focus is on constructing disease models or conducting pre-IND safety and toxicity studies, there are significant challenges associated with preclinical NHP or large animal studies for AAV-based gene therapy.

Explore solutions to challenges like high costs, low consistency, toxicity to animals, and immune responses due to AAV impurities. Learn how highly purified AAV enhances safety, efficacy, and data reproducibility. Delve into discussions on how rigorous standards, such as precise titer measurements, AAV genome integrity, Capsid characterization, impurity control, and safety measures minimize confounding factors and elevate the accuracy of your study.

On-demand video


2:00-3:00 PM EST (11:00 am-12:00 pm PST). Jan 31, 2024



Name: Irene Song
Company: PackGene Biotech
Title: Sr. Director, Global Product

Irene Song. Ph.D. is the Senior Director of Global Product PackGene Biotech, Inc., since February 2023. Prior to this, she worked at GenScript as Head of Product Management, Molecular Biology; Irene’s diverse expertise extends to her post-doctoral research at the Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, focusing on the mechanisms of Parkinson’s Disease. She holds a Ph.D.in Cell and Developmental Biology from the University of California, with research spanning a chemical genetics approach to understanding mitochondrial behavior in mammalian cell physiology, apoptosis, and the mechanism of Dominant Optic Atrophy (DOA).

Related services:


AAV Packaging (NHP Grade)

Premium AAV Packaging specifically designed for Non-Human Primates studies


[Video] Webinar: Overcoming Challenges in Preclinical NHP and Large Animal Studies for AAV-Based Gene Therapy through Improved AAV Purification and Quality Control Strategies